Drug Eluting Stent Sales

Drug Eluting Stent Sales Market Outlook

The global Drug Eluting Stent (DES) market was valued at approximately $5.7 billion in 2023 and is projected to reach around $9.4 billion by 2035, growing at a CAGR of 5.1% during the forecast period from 2025 to 2035. Factors driving this growth include the increasing prevalence of cardiovascular diseases, advancements in stent technology, and a rising elderly population. Moreover, the growing demand for minimally invasive procedures and continuous investments in healthcare infrastructure contribute significantly to the flourishing DES market. Furthermore, favorable reimbursement policies and an increase in healthcare expenditure across various regions are expected to propel market growth in the coming years.

Growth Factor of the Market

The Drug Eluting Stent market is witnessing significant growth driven by multiple factors. Firstly, the surge in coronary artery diseases (CAD) due to unhealthy lifestyle choices, including obesity, lack of physical activity, and smoking, has led to increased demand for effective treatment options. Additionally, the advent of cutting-edge technologies in stent design, such as biodegradable polymers and innovative drug delivery systems, has improved patient outcomes and reduced the risk of restenosis, thereby enhancing adoption rates. The expansion of healthcare facilities and increasing per capita healthcare expenditure, especially in developing regions, continue to provide a substantial boost to the market. Moreover, the rising awareness about advanced cardiac procedures and the effectiveness of drug-eluting stents in preventing the recurrence of blockages are influencing the purchasing decisions of healthcare providers. Lastly, regulatory approvals for new and improved stent products have also played a crucial role in catalyzing market growth.

Key Highlights of the Market

• The Drug Eluting Stent market is expected to grow at a CAGR of 5.1% from 2025 to 2035.
• Increasing prevalence of coronary artery diseases is driving the demand for drug-eluting stents.
• Advancements in stent technology, such as biodegradable polymers, are enhancing patient outcomes.
• Rising healthcare expenditure and investments in healthcare infrastructure are boosting market growth.
• Favorable reimbursement policies are supporting the adoption of drug-eluting stents globally.

By Product Type

Polymer-Based Drug Eluting Stents:

Polymer-based drug-eluting stents (DES) dominate the market due to their proven effectiveness in reducing restenosis rates. These stents utilize a polymer coating to gradually release anti-proliferative drugs, preventing the growth of cells that cause blockage. The most common drugs used in these stents include sirolimus and paclitaxel. The polymer coating not only delivers the drug effectively but also aids in the adhesion and integration of the stent with the artery wall. Continuous innovations to improve the biocompatibility and durability of these polymers have further enhanced their appeal among healthcare professionals. Additionally, the increasing number of coronary interventions is expected to sustain the growth of this segment, as polymer-based solutions continue to be a preferred choice for many cardiologists.

Polymer-Free Drug Eluting Stents:

Polymer-free drug-eluting stents are gaining traction in the market due to their unique design that eliminates the use of polymers while still effectively delivering drugs. These stents utilize a metallic structure that allows drugs to be released directly from the stent surface. The primary advantage of polymer-free stents is the reduced risk of late thrombosis, a complication associated with traditional polymer-based designs. As a result, they offer a safer option for patients at risk of adverse reactions to polymers. With the increasing focus on patient safety and the demand for simpler, more effective stenting solutions, the polymer-free segment is expected to witness significant growth in the coming years, especially in regions with high rates of coronary artery disease.

Biodegradable Polymer Drug Eluting Stents:

The biodegradable polymer drug-eluting stents segment is characterized by stents that utilize polymers that dissolve over time, leaving no permanent foreign body in the artery. This innovation addresses concerns over long-term complications associated with traditional stents. By gradually releasing the drug and subsequently degrading, these stents support the healing process of the arterial wall without causing chronic inflammatory responses. The rising preference for biocompatible and bioresorbable stents, especially among patients undergoing elective procedures, is driving this segment's growth. As regulatory agencies continue to approve more biodegradable options, this segment is set for robust expansion, catering well to the evolving landscape of cardiovascular treatment.

Metallic Drug Eluting Stents:

Metallic drug-eluting stents remain a cornerstone in the treatment of coronary artery disease and peripheral vascular interventions. These stents are typically made from stainless steel or cobalt-chromium alloys and are coated with drugs that inhibit cell proliferation. The metallic stents provide excellent radial strength and durability, which is crucial for maintaining vessel patency. Moreover, advancements in metallic stents, including the development of thin-strut designs and improved drug formulations, have enhanced their effectiveness and reduced complications. As the first generation of DES, metallic stents continue to dominate the market, particularly in regions where traditional approaches are still favored due to cost-effectiveness and availability.

Others:

This category encompasses a variety of novel stenting technologies, including bioengineered stents and those with unique drug formulations or combinations. These innovations aim to address specific clinical needs, such as improving drug release kinetics or targeting multiple pathways involved in vascular healing. The growth in this segment is primarily driven by ongoing research and development efforts within the field of interventional cardiology. As healthcare providers seek new solutions for complex cases, the demand for alternative stent technologies is expected to rise, providing opportunities for niche players to introduce innovative products tailored to specific patient populations.

By Application

Coronary Artery Disease:

Coronary artery disease (CAD) is the leading application segment for drug-eluting stents, accounting for a substantial share of the overall market. The increasing incidence of CAD due to lifestyle factors, such as obesity and smoking, has led to an uptick in percutaneous coronary interventions (PCIs) where these stents are frequently utilized. These stents significantly improve patient outcomes by reducing the likelihood of restenosis compared to bare-metal stents. Furthermore, ongoing clinical trials and studies that demonstrate the long-term efficacy and safety of drug-eluting stents for CAD continue to support their widespread adoption among healthcare providers. As diagnostic technologies improve and early detection of CAD becomes more common, the market for drug-eluting stents in this application is poised for sustained growth.

Peripheral Artery Disease:

The peripheral artery disease (PAD) application segment is gaining attention due to the rising prevalence of vascular diseases linked to aging populations and increasing rates of diabetes and obesity. Drug-eluting stents play a pivotal role in treating blockages in peripheral arteries, particularly in lower extremities, improving blood flow and reducing the risk of amputation. The innovative designs of PAD drug-eluting stents offer better delivery of therapeutic agents directly to the site of blockage, enhancing healing and vessel patency. As awareness of PAD rises and more patients seek treatment for symptoms, such as leg pain and non-healing wounds, the market for drug-eluting stents in this area is expected to grow robustly, supported by improved healthcare access.

Others:

This segment includes applications beyond CAD and PAD, such as treatment for renal artery stenosis and other vascular interventions. The demand for drug-eluting stents in these applications is driven by advancements in catheter-based procedures and improved imaging technologies that enable more accurate diagnosis and treatment. As interventional techniques evolve, healthcare providers are increasingly utilizing drug-eluting stents in complex cases where traditional methods may be less effective. The diversification of applications for drug-eluting stents is indicative of their versatility and the ongoing shift towards more comprehensive vascular treatment options, which is likely to fuel market growth.

By Distribution Channel

Hospitals:

Hospitals serve as the primary distribution channel for drug-eluting stents, accounting for a significant portion of sales in this market. Many cardiac procedures, including the implantation of drug-eluting stents, are performed in hospital settings due to the availability of specialized equipment, skilled personnel, and immediate access to emergency medical care if complications arise. The increasing number of heart surgeries and interventional procedures performed in hospitals, fueled by a growing aging population and rising prevalence of cardiovascular diseases, is propelling the demand for drug-eluting stents in this channel. Moreover, hospitals often have established relationships with stent manufacturers and suppliers, ensuring a steady supply of these critical devices.

Cardiology Centers:

Cardiology centers are emerging as important distribution channels for drug-eluting stents, particularly as outpatient procedures become more common. These centers are often equipped with the specialized technology needed for cardiac interventions, making them an attractive option for patients seeking minimally invasive procedures. The increasing preference for outpatient care, combined with the growing awareness of heart disease, has led to an uptick in procedures performed at cardiology centers. As more patients opt for treatment at these specialized facilities, the demand for drug-eluting stents is expected to rise, providing opportunities for manufacturers to expand their market presence in this segment.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) represent a growing distribution channel for drug-eluting stents, particularly in the context of outpatient cardiovascular interventions. These facilities often offer lower costs and increased convenience for patients, making them an appealing option for elective procedures. The rising trend towards outpatient surgeries, paired with advancements in stent technologies that allow for shorter recovery times, is driving demand in this channel. As ASCs continue to gain popularity, particularly for non-emergency procedures, the market for drug-eluting stents is likely to receive a boost, allowing patients to benefit from quicker access to care and enhanced overall experience.

Others:

The "Others" segment encompasses various alternative distribution channels, including home healthcare settings and specialty pharmacies. Although these channels account for a smaller portion of overall sales, they are increasingly important as the healthcare landscape evolves. With the rise of telemedicine and home-based therapies, there is potential for drug-eluting stents to be integrated into a broader range of treatment options. Additionally, the collaboration between manufacturers and specialty pharmacies to enhance patient access and education about stent technologies is expected to support growth in these non-traditional distribution channels. As healthcare continues to shift towards more integrated and patient-centric approaches, this segment may see increased relevance in the market.

By Drug Type

Sirolimus-Eluting Stents:

Sirolimus-eluting stents have been a cornerstone in the drug-eluting stent market since their introduction. They utilize the drug sirolimus, which inhibits cell proliferation and inflammation, significantly reducing the risk of restenosis after coronary interventions. Extensive clinical data supporting their long-term efficacy and safety has made them a preferred choice among cardiologists globally. As ongoing research continues to refine sirolimus formulations, improving drug delivery mechanisms and stent design, the demand for sirolimus-eluting stents remains strong. Additionally, the rising number of patients undergoing coronary artery interventions further bolsters this segment, establishing it as a critical component of the drug-eluting stent market.

Paclitaxel-Eluting Stents:

Paclitaxel-eluting stents have gained considerable traction due to their effectiveness in preventing restenosis and promoting improved patient outcomes. The use of paclitaxel, a well-known chemotherapy drug, significantly reduces cell growth within the arterial wall, allowing for better healing following stent placement. Despite facing scrutiny regarding safety in some studies, regulatory agencies have reaffirmed the clinical value of paclitaxel-eluting stents, especially in patients with high restenosis risk. As healthcare providers become more aware of the benefits and risks associated with different drug types, paclitaxel-eluting stents continue to maintain a strong presence in the market.

Zotarolimus-Eluting Stents:

Zotarolimus-eluting stents are gaining popularity due to their unique mechanism of action, which differs from that of sirolimus and paclitaxel. Zotarolimus has been shown to reduce neointimal hyperplasia effectively and is associated with lower rates of late stent thrombosis. Clinical trials have demonstrated favorable outcomes in terms of safety and efficacy, leading to increased acceptance of these stents among cardiologists. As advancements in zotarolimus-eluting technology continue to emerge, including improvements in stent design and drug delivery systems, this segment is expected to grow, driven by the desire for effective and safe interventional solutions.

Everolimus-Eluting Stents:

Everolimus-eluting stents represent another key segment in the drug-eluting stent market, known for their excellent clinical outcomes. Everolimus is an analog of sirolimus and shares a similar mechanism of action in inhibiting cell proliferation. The major advantage of everolimus-eluting stents is their favorable long-term safety profile and effectiveness in preventing restenosis. This has led to their widespread use in both routine and complex coronary interventions. As more clinical data continues to support their use in diverse patient populations, the demand for everolimus-eluting stents is expected to increase, solidifying their place in modern cardiology practices.

Others:

The "Others" category includes a variety of investigational drug-eluting stents that utilize alternative drugs or unique combinations of agents designed to optimize clinical outcomes. Research is ongoing to explore new formulations and combinations that may outperform existing options in terms of efficacy and safety. The segment's growth is primarily driven by continued innovation and the need for tailored solutions for specific patient needs. As regulatory approvals are granted for these novel stents, their presence in the market is anticipated to expand, offering healthcare providers more choices to effectively address the challenges associated with coronary artery disease.

By Region

The North American region holds a significant share of the global drug-eluting stent market, driven by the high prevalence of cardiovascular diseases and advanced healthcare infrastructure. The market in North America is projected to grow at a CAGR of 4.9% over the forecast period, supported by increasing awareness of advanced interventions and sustained investments in medical technology. Furthermore, favorable reimbursement policies and a well-established network of hospitals and cardiology centers contribute to the market's expansion in this region. The increasing adoption of minimally invasive procedures and ongoing clinical trials evaluating the efficacy of new drug-eluting stent technologies are expected to further bolster growth.

Europe is also a prominent player in the drug-eluting stent market, characterized by extensive research and development initiatives and high healthcare spending. The European market is anticipated to experience steady growth, driven by an aging population and rising incidences of coronary artery disease. Countries like Germany, France, and the UK are leading contributors to market growth due to their advanced healthcare systems and access to cutting-edge medical devices. Additionally, the growing popularity of outpatient procedures and the introduction of innovative stent designs are expected to enhance market performance in Europe, fostering a competitive environment for key players.

Opportunities

The Drug Eluting Stent market presents numerous opportunities for growth, particularly in emerging economies where healthcare infrastructure is expanding rapidly. As countries in Asia Pacific, Latin America, and the Middle East & Africa invest in upgrading their healthcare systems, the demand for advanced medical devices like drug-eluting stents is likely to rise. This presents a significant opportunity for stent manufacturers to enter these markets and establish distribution channels. Furthermore, increasing patient awareness and access to healthcare services are expected to drive the adoption of drug-eluting stents in these regions. Partnerships with local healthcare providers and governments can aid in navigating regulatory landscapes and securing a foothold in these burgeoning markets, allowing companies to capitalize on the rising need for cardiovascular interventions.

In addition to geographic expansion, the ongoing advancements in stent technology present a ripe opportunity for innovation within the market. Developing next-generation drug-eluting stents that have enhanced drug delivery mechanisms, biocompatibility, and flexible designs can attract the attention of healthcare providers seeking better solutions for their patients. As clinical research continues to validate the efficacy of new formulations and approaches, manufacturers that prioritize research and development will likely secure a competitive edge in the market. The growing trend toward personalized medicine, where treatment options are tailored to individual patient profiles, further underscores the importance of innovation in designing drug-eluting stents that meet diverse patient needs.

Threats

The Drug Eluting Stent market faces several threats that could potentially hinder growth, particularly from the emergence of alternative treatment methods. With the advent of drug-coated balloons and bioresorbable scaffolds, healthcare providers are increasingly exploring these less invasive options that may offer similar benefits without the long-term implantation of foreign devices. These alternatives pose a competitive threat to traditional drug-eluting stents and could lead to decreased market share if they gain widespread acceptance. Additionally, regulatory challenges and tighter scrutiny of device safety and efficacy may result in delays for new products entering the market, affecting manufacturers' ability to innovate and compete effectively in an evolving landscape.

Moreover, concerns surrounding complications associated with drug-eluting stents, such as late stent thrombosis, can deter healthcare providers from recommending these devices. Patients experiencing adverse events may have a decreased trust in drug-eluting technologies, leading to lower adoption rates. The need for extensive clinical data to address these safety concerns can also create barriers for entry for new products. Lastly, price pressures from healthcare systems and payers aiming to reduce costs can impact profit margins for manufacturers, requiring them to constantly balance innovation with affordability to maintain a competitive position in the market.

Competitor Outlook

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic PLC
• Terumo Corporation
• Johnson & Johnson
• Cardinal Health
• B. Braun Melsungen AG
• Cook Medical
• Stentys S.A.
• Spectranetics Corporation
• MicroPort Scientific Corporation
• OrbusNeich Medical
• Jiangsu ConvaTec Medical Technology
• Striker Corporation
• InspireMD, Inc.

The competitive landscape of the Drug Eluting Stent market is characterized by a mix of established global players and emerging companies focused on innovation. Major companies, such as Abbott Laboratories and Boston Scientific Corporation, lead the market through their extensive product portfolios and strong brand recognition. These companies have invested heavily in research and development to innovate next-generation drug-eluting technologies, enhancing patient outcomes and adhering to evolving regulatory standards. Their established distribution networks and partnerships with healthcare institutions allow them to maintain a competitive edge, ensuring widespread access to their products. The competition is further intensified by the presence of numerous regional players who offer localized solutions to meet the specific needs of their markets.

Abbott Laboratories is a key player in the Drug Eluting Stent sector, known for its innovative stent designs and commitment to quality. Their ever-expanding product line includes the everolimus-eluting stent, which has gained strong acceptance among healthcare providers due to its proven safety and efficacy. With a robust marketing strategy and continuous focus on clinical research, Abbott is well-positioned to capitalize on emerging trends and address the growing demand for cardiovascular interventions.

Boston Scientific Corporation has established itself as a leader in the drug-eluting stent market, driven by its comprehensive portfolio of devices designed for a variety of vascular interventions. Their innovative technologies, coupled with strategic partnerships and collaborations with healthcare providers, play a crucial role in enhancing their market presence. Boston Scientific's ongoing commitment to advancing treatment options through research and development ensures that they remain at the forefront of the industry, addressing the evolving needs of patients and providers alike.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Cook Medical
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Stentys S.A.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic PLC
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Cardinal Health
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 InspireMD, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Johnson & Johnson
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 OrbusNeich Medical
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Terumo Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Abbott Laboratories
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Striker Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 B. Braun Melsungen AG
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Spectranetics Corporation
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Boston Scientific Corporation
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 MicroPort Scientific Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Jiangsu ConvaTec Medical Technology
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Drug Eluting Stent Sales Market, By Drug Type
    • 6.1.1 Sirolimus-Eluting Stents
    • 6.1.2 Paclitaxel-Eluting Stents
    • 6.1.3 Zotarolimus-Eluting Stents
    • 6.1.4 Everolimus-Eluting Stents
    • 6.1.5 Others
  • 6.2 Drug Eluting Stent Sales Market, By Application
    • 6.2.1 Coronary Artery Disease
    • 6.2.2 Peripheral Artery Disease
    • 6.2.3 Others
  • 6.3 Drug Eluting Stent Sales Market, By Product Type
    • 6.3.1 Polymer-Based Drug Eluting Stents
    • 6.3.2 Polymer-Free Drug Eluting Stents
    • 6.3.3 Biodegradable Polymer Drug Eluting Stents
    • 6.3.4 Metallic Drug Eluting Stents
    • 6.3.5 Others
  • 6.4 Drug Eluting Stent Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Cardiology Centers
    • 6.4.3 Ambulatory Surgical Centers
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Drug Eluting Stent Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Drug Eluting Stent Sales market is categorized based on

By Product Type

• Polymer-Based Drug Eluting Stents
• Polymer-Free Drug Eluting Stents
• Biodegradable Polymer Drug Eluting Stents
• Metallic Drug Eluting Stents
• Others

By Application

• Coronary Artery Disease
• Peripheral Artery Disease
• Others

By Distribution Channel

• Hospitals
• Cardiology Centers
• Ambulatory Surgical Centers
• Others

By Drug Type

• Sirolimus-Eluting Stents
• Paclitaxel-Eluting Stents
• Zotarolimus-Eluting Stents
• Everolimus-Eluting Stents
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Abbott Laboratories
• Boston Scientific Corporation
• Medtronic PLC
• Terumo Corporation
• Johnson & Johnson
• Cardinal Health
• B. Braun Melsungen AG
• Cook Medical
• Stentys S.A.
• Spectranetics Corporation
• MicroPort Scientific Corporation
• OrbusNeich Medical
• Jiangsu ConvaTec Medical Technology
• Striker Corporation
• InspireMD, Inc.